

Curriculum vitae

Personal details

Name Valentina Comunanza

Born in Italy (Susa, TO)

Nationality: Italian

Email: valentina.comunanza@unito.it

Website: https://www.oncology.unito.it/do/docenti.pl/Show?_id=vcomunan#tab-profilo

ORCID ID: 0000-0002-0695-6420

Scopus ID: 18834358700

Researcher ID: ID I-8645-2018

Educations

2011

PhD in Neuroscience

University of Torino, Italy

2008-2009

Exchange visitor (PhD program)

Eli Lilly and Company, Erl Wood Manor, Windlesham, Surrey (UK)

Pain and Migraine Laboratory

2006

Master Degree in Chemistry and Pharmaceutical Technologies

University of Torino, Italy

Professional experiences and current position

2022-present

Assistant Professor - RTDB

Department of Oncology, University of Torino

2019-2022

Research Technician

Tecnico della Ricerca a tempo determinato categoria D
area tecnica, tecnico-scientifica ed elaborazione dei dati

Department of Oncology, University of Torino

2018 – 2019

Postdoctoral research fellow (borsa di studio)

Title of the project: “Strategie per migliorare l'uso dei farmaci anti-angiogeneteci nei pazienti con tumori del colon-retto”

Department of Oncology, University of Torino

2017 – 2018

Postdoctoral research fellow (assegno di ricerca)

Title of the project: “Strategie per migliorare l'uso dei farmaci anti-angiogeneteci nei pazienti con tumori del colon-retto”

Department of Oncology, University of Torino

2015 – 2016

Postdoctoral research fellow (assegno di ricerca)

Title of the project: “Strumenti innovativi per la diagnosi precoce e l'analisi del rischio dei tumori del pancreas”

Department of Oncology, University of Torino

2013 – 2014

Postdoctoral research fellow (assegno di ricerca)

Title of the project: “Identificazioni e caratterizzazione di peptidi antagonisti di VEGFR2 mediante la tecnologia CONTACT ANGLE MOLECULAR RECOGNITION (CONAMORE)”

Department of Molecular and Translational Medicine, University of Brescia

2013

Postdoctoral research fellow (assegno di ricerca)

Title of the project: “Identificazione di fosfoproteine espresse dall'endotelio attivato”.

Department of Molecular and Translational Medicine, University of Brescia

2012 – 2013

Postdoctoral research fellow (assegno di ricerca)

Title of the project: “Ruolo di gremlin nella vascolarizzazione tumorale”.

Department of Biotechnology and Biomedicine, University of Brescia

2011 – 2012

Postdoctoral research fellow

Candiolo Institute IRCCS – FPO

Participation to Directive Boards of Scientific Societies and/or Institutions:

Honors

Teaching activity:

2023

Lecturer in Biochemistry (Biochimica d'organo) at School of Medicine, University of Torino

Research main topics

Main projects as PI:

2/02/2020 – 31/05/2022

Fondo per la Ricerca Locale 2020.

Host Institution: UNITO, Dipartimento di Oncologia

Title of the project: “Single-cell transcriptomics in BRAFV600E melanoma models identify biomarkers of acquired resistance to targeted and immune therapies

Bibliometry (2007-present) (www.scopus.com)

Research performance

Publications (Scopus) 24

H-index (Scopus)* 18

Citations (Scopus)* 670

Publications (Web of Science) 28
H-index (Web of Science) 17
Citations (Web of Science) 649

*self-citations excluded

10 best publications

1. **COMUNANZA V**, Corà D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. (2017). VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. *EMBO MOLECULAR MEDICINE*, vol. 9, p. 219-237, ISSN: 1757-4676, doi: 10.15252/emmm.201505774
2. Brancato V*, **COMUNANZA V***, Imperato G, Corà D, Urciuolo F, Noghero A, Bussolino F, Netti, P. (2017). Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer. *ACTA BIOMATERIALIA*, vol. 49, p. 152-156, ISSN: 1742-7061, doi: dx.doi.org/10.1016/j.actbio.2016.11.072 - *These two authors contributed equally to this work.
3. **COMUNANZA V**, Bussolino F (2017). Therapy for cancer: Strategy of combining anti-angiogenic and target therapies. *FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY*, vol. 5, p. 1-18, ISSN: 2296-634X, doi: 10.3389/fcell.2017.00101
4. **COMUNANZA V**, Marcantoni A, Vandael DHF, Mahapatra S, Gavello D, Navarro Tableros V, Carabelli V, Carbone E. (2010). CaV1.3 as pacemaker channels in adrenal chromaffin cells: Specific role on exo- and endocytosis?. *CHANNELS*, vol. 4, p. 440-446, ISSN: 1933-6950, doi:10.4161/chan.4.6.12866
5. **COMUNANZA V**, Carbone E, Marcantoni A, Sher E, Ursu D (2011). Calcium-dependent inhibition of T-type calcium channels by TRPV1 activation in rat sensory neurons. *PFLÜGERS ARCHIV*, vol. 462, p. 709-722, ISSN: 0031-6768, doi: 10.1007/s00424-011-1023-5
6. Cencioni C*, **COMUNANZA V***, Middonti E, Vallariello E, Bussolino F (2021). The role of redox system in metastasis formation. *ANGIOGENESIS*, p. 1-20, ISSN: 0969-6970, doi: 10.1007/s10456-021-09779-5 *These two authors contributed equally to this work.
7. Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbo F, Cartia CF, Passone E, **COMUNANZA V**, Ardisson F, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C. (2019). Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma. *JOURNAL OF THORACIC ONCOLOGY*, vol. 14, p. 1458-1471, ISSN: 1556-0864, doi: 10.1016/j.jtho.2019.03.029
8. Doronzo G, Astanina E, Corà D, Chiabotto G, **COMUNANZA V**, Noghero A, Neri F, Puliafito A, Primo L, Spanpanato C, Settembre C, Ballabio A, Camussi G, Oliviero S, Bussolino F. (2019). TFEB controls vascular development by regulating the proliferation of endothelial cells. *EMBO JOURNAL*, vol. 38, p. e98250-e98273, ISSN: 0261-4189, doi: 10.15252/embj.201798250
9. Pasquardini L, Pancheri L, Potrich C, Ferri A, Piemonte C, Lunelli L, Napione L, **COMUNANZA V**, Alvaro M, Vanzetti L, Bussolino F, Pederzoli C. (2015). SPAD aptasensor for the detection of circulating protein biomarkers. *BIOSENSORS & BIOELECTRONICS*, vol. 68, p. 500-507, ISSN: 0956-5663, doi: 10.1016/j.bios.2015.01.042
10. Bottos A, Martini M, Di Nicolantonio F, **COMUNANZA V**, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. (2012). Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*, vol. 109, p. E353-E359, ISSN: 0027-8424, doi: 10.1073/pnas.1105026109

15 more relevant publication in the last 5 yrs (2018-2022)

1. Salaroglio IC, Belisario DC, Bironzo P, Ananthanarayanan P, Ricci L, Digiovanni S, Fontana S, Napoli F, Sandri A, Facolmatà C, Libener R, **COMUNANZA V** Grosso F, Gazzano E, Leo F, Taulli R, Bussolino F, Righi L, Papotti MG, Novello S, Scagliotti GV, Riganti C, Kopecka J (2022) SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. *J Exp Clin Cancer Res.* 2022 Feb 23;41(1):75. doi: 10.1186/s13046-022-02284-7.
2. Cencioni C*, **COMUNANZA V***, Middonti E, Vallariello E, Bussolino F (2021). The role of redox system in metastasis formation. *ANGIOGENESIS*, p. 1-20, ISSN: 0969-6970, doi: 10.1007/s10456-021-09779-*These two authors contributed equally to this work.
3. Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, **COMUNANZA V**, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. (2021) Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. *Cancers (Basel)*. 2021 May 12;13(10):2332. doi: 10.3390/cancers13102332.
4. Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, Orecchia S, Ananthanarayanan P, Bironzo P, Grosso F, Tabbò F, **COMUNANZA V**, Alexa-Stratulat T, Bussolino F, Righi L, Novello S, Scagliotti GV, Riganti C. (2020) Wnt/IL-1 β /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. *Int J Cancer*. 2020 Jan 1;146(1):192-207. doi: 10.1002/ijc.32419. Epub 2019 Jun 4.
5. Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, Gagliasso M, Milosevic V, Ananthanarayanan P, Bironzo P, Tabbo F, Cartia CF, Passone E, **COMUNANZA V**, Ardisson E, Ruffini E, Bussolino F, Righi L, Novello S, Di Maio M, Papotti M, Scagliotti GV, Riganti C. (2019). Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma. *JOURNAL OF THORACIC ONCOLOGY*, vol. 14, p. 1458-1471, ISSN: 1556-0864, doi: 10.1016/j.jtho.2019.03.029
6. Doronzo G, Astanina E, Corà D, Chiabotto G, **COMUNANZA V**, Noghero A, Neri F, Puliafito A, Primo L, Spanpanato C, Settembre C, Ballabio A, Camussi G, Oliviero S, Bussolino F. (2019). TFEB controls vascular development by regulating the proliferation of endothelial cells. *EMBO JOURNAL*, vol. 38, p. e98250-e98273, ISSN: 0261-4189, doi: 10.15252/embj.201798250
7. **COMUNANZA V**. (2018) Targeting mPGES-1 as a New Strategy against Neuroblastoma. *EBioMedicine*. 2018 Jul;33:14-15. doi: 10.1016/j.ebiom.2018.06.008. Epub 2018 Jun 12.
8. di Blasio L, Puliafito A, Gagliardi PA, **COMUNANZA V**, Somale D, Chiaverina G, Bussolino F, Primo L. (2018) PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. *Cell Death Dis.* 2018 Jan 19;9(2):45. doi: 10.1038/s41419-017-0064-x.
9. Riganti C, Lingua MF, Salaroglio IC, Falcomatà C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, **COMUNANZA V**, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R. (2018) Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. *Oncoimmunology*. 2017 Nov 27;7(3):e1398874. doi: 10.1080/2162402X.2017.1398874. eCollection 2018.